このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Genfit マネジメント

マネジメント基準チェック /44

Genfit'sの CEO はM. Prigentで、 Sep2019年に任命され、の在任期間は 5.08年です。の年間総報酬は€ 664.22Kで、 59.3%給与と40.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.062%を直接所有しており、その価値は€ 166.74K 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と7.3年です。

主要情報

M. Prigent

最高経営責任者

€664.2k

報酬総額

CEO給与比率	59.3%
CEO在任期間	5.1yrs
CEOの所有権	0.06%
経営陣の平均在職期間	2.8yrs
取締役会の平均在任期間	7.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Genfit の収益と比較して、M. Prigent の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	€22m
Mar 31 2024	n/a	n/a	-€3m
Dec 31 2023	€664k	€394k	-€29m
Sep 30 2023	n/a	n/a	-€32m
Jun 30 2023	n/a	n/a	-€34m
Mar 31 2023	n/a	n/a	-€29m
Dec 31 2022	€632k	€375k	-€24m
Sep 30 2022	n/a	n/a	€12m
Jun 30 2022	n/a	n/a	€48m
Mar 31 2022	n/a	n/a	€58m
Dec 31 2021	€562k	€325k	€67m
Sep 30 2021	n/a	n/a	€14m
Jun 30 2021	n/a	n/a	-€39m
Mar 31 2021	n/a	n/a	-€70m
Dec 31 2020	€455k	€325k	-€101m
Sep 30 2020	n/a	n/a	-€84m
Jun 30 2020	n/a	n/a	-€67m
Mar 31 2020	n/a	n/a	-€66m
Dec 31 2019	€325k	€95k	-€65m

報酬と市場: M.の総報酬 ($USD 713.22K ) は、 UK市場 ($USD 741.15K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: M.の報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

M. Prigent (55 yo)

5.1yrs

在職期間

€664,224

報酬

Mr. M. Pascal Prigent has been Chief Executive Officer of Genfit SA since September 16, 2019. He served as Executive Vice President of Marketing & Commercial Development at Genfit SA since May 31, 2018 unt...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jean-Francois Mouney	Co-Founder & Chairman of the Board	7.3yrs	€359.01k	0.094% € 225.5k
M. Prigent	Chief Executive Officer	5.1yrs	€664.22k	0.062% € 148.6k
Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board	no data	データなし	データなし
Thomas Baetz	Chief Financial Officer	3.5yrs	データなし	データなし
Pascal Caisey	Chief Operating Officer	2.6yrs	データなし	0.0095% € 22.8k
Meriam Kabbaj	Chief Technology Officer	1.8yrs	データなし	データなし
Dean Hum	Chief Scientific Officer	2.8yrs	€795.03k	0.021% € 49.8k
Jean-Christophe Marcoux	Chief Corporate Affairs Officer	1.6yrs	データなし	0.0094% € 22.6k
Laurent Lannoo	Corporate Secretary & Director of Legal Affairs	16.8yrs	データなし	0.023% € 54.4k
Stefanie Magner	Chief Compliance Officer & Executive VP of International Legal Affairs	3.6yrs	データなし	0.0055% € 13.4k
Emilie Desodt	Executive Vice President of Human Resources	2.6yrs	データなし	0.0035% € 8.4k
Sakina Sayah-Jeanne	Executive VP of Research & Translational Science	1.5yrs	データなし	データなし

2.8yrs

平均在職期間

52.5yo

平均年齢

経験豊富な経営陣: 0QT6の経営陣は経験豊富であると考えられます ( 2.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jean-Francois Mouney	Co-Founder & Chairman of the Board	7.3yrs	€359.01k	0.094% € 225.5k
Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board	no data	データなし	データなし
Philippe Moons	Board Observer	3.7yrs	€7.63k	0.0021% € 5.0k
Florence Séjourné	Director	7.3yrs	データなし	データなし
Scott L. Friedman	Member of Scientific Advisory Board	no data	データなし	データなし
Arun Sanyal	Member of Scientific Advisory Board	no data	データなし	データなし
Michael Trauner	Member of Scientific Advisory Board	no data	データなし	データなし
Catherine Larue	Independent Director	7.3yrs	€43.60k	データなし
Vlad Ratziu	Member of Scientific Advisory Board	no data	データなし	データなし
Anne-Helene Monsellato	Independent Director	7.3yrs	€39.24k	データなし
Katherine Kalin	Independent Director	4.3yrs	€39.24k	0.010% € 24.2k
Eric Baclet	Independent Vice-Chairman of the Board	4.3yrs	€47.96k	0.0024% € 5.8k

7.3yrs

平均在職期間

62.5yo

平均年齢

経験豊富なボード: 0QT6の取締役会は経験豊富であると考えられます ( 7年の平均在任期間)。

Genfit マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Insufficient new directors

Genfit S.A., Annual General Meeting, May 22, 2024

GENFIT Announces Board Changes

Genfit SA, Annual General Meeting, May 28, 2021

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT

Recent updates

Investor sentiment improves as stock rises 25%

First half 2024 earnings released: EPS: €0.61 (vs €0.42 loss in 1H 2023)

New major risk - Share price stability

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

New minor risk - Share price stability

Full year 2023 earnings released: €0.58 loss per share (vs €0.48 loss in FY 2022)

Insufficient new directors

Genfit S.A., Annual General Meeting, May 22, 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

GENFIT Announces Publication in Nature Medicine Confirming the Performance of Its Nash Diagnostic Technology

First half 2023 earnings released: €0.42 loss per share (vs €0.21 loss in 1H 2022)

New minor risk - Profitability

Genfit S.A. Announces the Publication of New Data on the Clinical Performance of NIS2+(TM) in Older Patients in Hepatology Communications

New minor risk - Profitability

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week as part of its ACLF Program

Full year 2022 earnings released: €0.48 loss per share (vs €1.50 profit in FY 2021)

Genfit S.A. to Report First Half, 2023 Results on Sep 20, 2023

Genfit S.A. (ENXTPA:GNFT) acquired Versantis AG for approximately CHF 110 million.

First half 2022 earnings released: €0.21 loss per share (vs €0.21 profit in 1H 2021)

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG for approximately CHF 110 million.

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG from a group of investors for approximately CHF 110 million.

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: €1.51 (vs €2.61 loss in FY 2020)

Forecast to breakeven in 2022

First half 2021 earnings released: EPS €0.21 (vs €1.36 loss in 1H 2020)

GENFIT Presents New NIS4® Data in NASH at the International Liver Congress™ and the 81St Scientific Sessions of the American Diabetes Association

GENFIT Announces the Launch of NASHnext®, a Novel, Noninvasive Diagnostic Test for Nonalcoholic Steatohepatitis

Full year 2020 earnings released: €2.60 loss per share (vs €1.76 loss in FY 2019)

Full year 2020 earnings released

GENFIT Announces Board Changes

Genfit SA to Report Fiscal Year 2020 Results on Apr 01, 2021

Genfit SA, Annual General Meeting, May 28, 2021

New 90-day high: €5.16

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT

New 90-day high: €4.78

Robbins LLP Announces That Purchaser of Genfit SA American Depository Shares Filed Class Action Complaint Against the Company and Its Officers and Directors for Alleged Violations of the Securities Act of 1933

Genfit Presents New Data at AASLD The Liver Meeting Digital Experience™

New 90-day low: €3.09

Genfit and Labcorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

First half earnings released

GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC

Genfit SA to Report First Half, 2020 Results on Sep 30, 2020

New 90-day low: €3.60

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44